NCT01314105View on ClinicalTrials.gov

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 15, 2011

Primary Completion Date

July 29, 2013

Study Completion Date

April 4, 2016

Conditions
Ovarian NeoplasmsPeritoneal Neoplasms
Interventions
DRUG

BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF1120 twice daily along with standard therapy of PLD + carboplatin

DRUG

BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF1120 twice daily along with standard therapy of PLD + carboplatin

DRUG

BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

BIBF1120 twice daily along with standard therapy of PLD + carboplatin

Trial Locations (3)

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08907

Hospital Duran i Reynals, L'Hospitalet de Llobregat

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01314105 - BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter